Leo Pharma taps Morphosys to fuel dermatology ambitions
By Michael Fitzhugh
Staff Writer
Staff Writer
Wednesday, November 2, 2016
Leo Pharma A/S is again raising its bet on the promise of biologics to address important skin diseases, dealing in Morphosys AG and its Ylanthia antibody platform for a multi-target deal.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.